ClearPoint Neuro (CLPT) Stock Skyrockets on Brain Therapy Breakthroughs – 2025 Deep Dive
ClearPoint Neuro shares surged to the mid-$20s in November 2025 after hitting a 52-week high near $30, driven by heavy trading and recent product breakthroughs. The company reported Q2 revenue of $9.2 million, up 17% year-on-year, but remains unprofitable. Its neuro devices gained expanded FDA clearance and international approvals. Analysts maintain buy ratings with price targets averaging $29.
